Somewhat Positive Press Coverage Somewhat Unlikely to Affect The Medicines (MDCO) Stock Price

News articles about The Medicines (NASDAQ:MDCO) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Medicines earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.9416467633827 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

MDCO has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and set a $85.00 price target on shares of The Medicines in a report on Wednesday, September 20th. Jefferies Group LLC restated a “buy” rating and set a $54.00 price target on shares of The Medicines in a report on Thursday, September 14th. Zacks Investment Research upgraded The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Tuesday, August 8th. Cowen and Company restated a “buy” rating and set a $54.00 price target (down from $61.00) on shares of The Medicines in a report on Thursday, August 10th. Finally, Guggenheim initiated coverage on The Medicines in a report on Monday, October 23rd. They set a “buy” rating and a $45.00 price target for the company. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The Medicines has a consensus rating of “Buy” and an average price target of $53.18.

The Medicines (MDCO) traded down 3.90% during midday trading on Friday, reaching $28.30. The company had a trading volume of 2,388,965 shares. The firm has a 50-day moving average of $35.07 and a 200 day moving average of $39.46. The Medicines has a 1-year low of $28.00 and a 1-year high of $55.95. The company’s market capitalization is $2.06 billion.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative return on equity of 149.81% and a negative net margin of 767.94%. The company had revenue of $16.87 million for the quarter, compared to analyst estimates of $26.06 million. During the same period in the prior year, the company posted ($0.64) EPS. The firm’s quarterly revenue was down 55.1% compared to the same quarter last year. On average, equities research analysts forecast that The Medicines will post ($9.21) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Insider Buying and Selling by Quarter for The Medicines (NASDAQ:MDCO)

What are top analysts saying about The Medicines Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines Company and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit